EdgeMarket › What Baker Bros. Advisors Lp reported owning
What Baker Bros. Advisors Lp reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
17.4BPositions
84Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| INCY INCYTE CORP | 2.9B | 16.6% | 30.7M | 127.81 | +48.3% |
| ONC BeOne Medicines Ltd. | 2.6B | 15.0% | 8.8M | 374.47 | +21.1% |
| INSM INSMED Inc | 1.2B | 7.0% | 7.4M | 125.77 | -2.8% |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | 1.1B | 6.4% | 2.1M | 516.74 | +31.9% |
| ACAD ACADIA PHARMACEUTICALS INC | 954.9M | 5.5% | 42.9M | 29.50 | +18.3% |
| RVMD Revolution Medicines, Inc. | 929.3M | 5.3% | 9.6M | 209.46 | +479.3% |
| CELC Celcuity Inc. | 903.5M | 5.2% | 7.9M | 93.53 | +91.8% |
| KOD Kodiak Sciences Inc. | 759.3M | 4.4% | 19.9M | 38.33 | +303.5% |
| KYMR Kymera Therapeutics, Inc. | 721.1M | 4.1% | 8.7M | 119.80 | +182.9% |
| SMMT Summit Therapeutics Inc. | 690.0M | 4.0% | 36.4M | 13.16 | -49.1% |
| PRAX Praxis Precision Medicines, Inc. | 564.9M | 3.2% | 1.8M | 375.94 | +730.8% |
| RYTM RHYTHM PHARMACEUTICALS, INC. | 487.4M | 2.8% | 5.6M | 110.00 | +11.4% |
| ALKS Alkermes plc. | 354.0M | 2.0% | 10.0M | 48.33 | +66.8% |
| GRAL GRAIL, Inc. | 208.2M | 1.2% | 4.0M | 79.54 | +147.2% |
| EWTX Edgewise Therapeutics, Inc. | 207.1M | 1.2% | 6.6M | 44.18 | +219.2% |
| IONS IONIS PHARMACEUTICALS INC | 153.8M | 0.9% | 2.0M | 59.74 | +39.5% |
| KNSA Kiniksa Pharmaceuticals International, plc | 136.1M | 0.8% | 2.8M | 79.03 | +138.0% |
| IMVT Immunovant, Inc. | 135.6M | 0.8% | 5.5M | 44.37 | +199.4% |
| ROIV Roivant Sciences Ltd. | 134.8M | 0.8% | 4.9M | 36.30 | +209.7% |
| IDYA IDEAYA Biosciences, Inc. | 131.5M | 0.8% | 3.9M | 39.67 | +63.1% |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | 124.9M | 0.7% | 2.0M | 87.11 | +331.2% |
| STOK Stoke Therapeutics, Inc. | 108.6M | 0.6% | 3.3M | 32.29 | +67.1% |
| IMTX Immatics N.V. | 107.4M | 0.6% | 10.9M | 8.93 | +59.5% |
| ABCL AbCellera Biologics Inc. | 105.7M | 0.6% | 30.3M | 11.32 | +171.5% |
| ABVX Abivax S.A. | 97.5M | 0.6% | 875.8K | 114.95 | +59.9% |
| CRNX Crinetics Pharmaceuticals, Inc. | 85.4M | 0.5% | 2.4M | 84.69 | +191.1% |
| REPL Replimune Group, Inc. | 84.5M | 0.5% | 11.0M | 14.77 | +181.3% |
| unmapped CUSIP 15102KAA8 | 74.9M | 0.4% | 30.8M | — | — |
| NRIX Nurix Therapeutics, Inc. | 72.2M | 0.4% | 4.7M | 26.72 | +180.4% |
| DNLI Denali Therapeutics Inc. | 71.6M | 0.4% | 3.7M | 24.92 | +71.7% |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 71.5M | 0.4% | 852.2K | 111.10 | +374.4% |
| GLUE Monte Rosa Therapeutics, Inc. | 71.5M | 0.4% | 4.3M | 14.30 | +222.8% |
| GPCR Structure Therapeutics Inc. | 69.0M | 0.4% | 1.4M | 49.09 | +164.4% |
| TRDA Entrada Therapeutics, Inc. | 64.0M | 0.4% | 5.1M | 7.57 | +42.6% |
| BCYC BICYCLE THERAPEUTICS PLC | 50.5M | 0.3% | 10.9M | 4.37 | -37.8% |
| SYRE Spyre Therapeutics, Inc. | 50.4M | 0.3% | 1.0M | 106.49 | +551.3% |
| RAPP Rapport Therapeutics, Inc. | 48.4M | 0.3% | 1.5M | 48.24 | +236.9% |
| ALMS ALUMIS INC. | 44.3M | 0.3% | 2.0M | 24.17 | +448.1% |
| MIRM Mirum Pharmaceuticals, Inc. | 41.2M | 0.2% | 446.0K | 96.31 | +44.4% |
| VRDN Viridian Therapeutics, Inc.\DE | 38.6M | 0.2% | 2.0M | 24.29 | +33.9% |
| ELVN Enliven Therapeutics, Inc. | 35.5M | 0.2% | 905.2K | 59.82 | +204.3% |
| PRLD Prelude Therapeutics Inc | 34.6M | 0.2% | 10.1M | 6.63 | +531.4% |
| DBVT DBV Technologies S.A. | 30.5M | 0.2% | 1.5M | 14.55 | +48.5% |
| DSGN Design Therapeutics, Inc. | 27.5M | 0.2% | 2.6M | 14.99 | +212.9% |
| unmapped CUSIP 152309100 | 26.6M | 0.2% | 670.8K | — | — |
| CTMX CytomX Therapeutics, Inc. | 23.4M | 0.1% | 5.0M | 3.28 | +66.5% |
| JBIO Jade Biosciences, Inc. | 23.1M | 0.1% | 1.6M | 21.34 | +211.5% |
| IRON Disc Medicine, Inc. | 22.4M | 0.1% | 349.7K | 79.81 | +35.9% |
| IMCR Immunocore Holdings plc | 22.1M | 0.1% | 734.4K | 36.88 | +13.5% |
| XENE Xenon Pharmaceuticals Inc. | 21.5M | 0.1% | 370.2K | 60.77 | +61.5% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →